Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2017
18th World Conference on Lung Cancer
Access to all presentations that occur during the 18th World Conference on Lung Cancer in Yokohama, Japan
Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Download PDF of the Conference Program: Click Here.
Presentations will be available 24 hours after their live presentation time
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Presentations: 25
- Moderators:C. Bai
- Coordinates: 10/15/2017, 07:30 - 11:30, F203 (Annex Hall)
-
+
JCSE 01.12 - A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
10:35 - 10:50 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE 01.24 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
11:30 - 11:30 | Presenter: Tony SK Mok
- Abstract
Loading...
-
+
P1.01 - Advanced NSCLC
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 80
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-032 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
09:30 - 09:30 | Presenter: Tony SK Mok
- Abstract
Loading... -
+
P1.01-037 - Circulating Tumor DNA Clearance During Treatment Associates with Improved Progression-Free Survival
09:30 - 09:30 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 13
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.04-010 - CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
09:30 - 09:30 | Presenter: Shun Lu
- Abstract
Loading...
-
+
MA 02 - Emerging Targets
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 12
- Moderators:Ravi Salgia
- Coordinates: 10/16/2017, 11:00 - 12:30, Room 511 + 512
-
+
MA 02.01 - Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors
11:00 - 11:05 | Presenter: Ticiana A. Leal
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.02 - Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
11:05 - 11:10 | Author(s): B.P. Levy
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.03 - Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study
11:10 - 11:15 | Presenter: Mark Awad
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.04 - Discussant - MA 02.01, MA 02.02, MA 02.03
11:15 - 11:30 | Presenter: Grace K Dy
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.05 - Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP)
11:30 - 11:35 | Author(s): A. Ardizzoni
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.06 - BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy
11:35 - 11:40 | Presenter: Elizabeth Dudnik
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.07 - A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
11:40 - 11:45 | Presenter: Aaron Lisberg
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.08 - Discussant - MA 02.05, MA 02.06, MA 02.07
11:45 - 12:00 | Presenter: Barbara Melosky
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.09 - A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC
12:00 - 12:05 | Presenter: Don Lynn Gibbons
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.10 - Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
12:05 - 12:10 | Presenter: Jonathan Wade Goldman
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.11 - A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
12:10 - 12:15 | Presenter: Jonathan W Riess
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA 02.12 - Discussant - MA 02.09, MA 02.10, MA 02.11
12:15 - 12:30 | Presenter: Dean A Fennell
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA 03 - Chemotherapy
- Type: Mini Oral
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:Jin-Hyoung Kang
- Coordinates: 10/16/2017, 11:00 - 12:30, Room 502
-
+
MA 03.03 - Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung
11:10 - 11:15 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA 08 - Supportive Care and Communication
- Type: Mini Oral
- Track: Nursing/Palliative Care/Ethics
- Presentations: 12
- Moderators:E. Esposito-Nguyen
- Coordinates: 10/17/2017, 11:00 - 12:30, Room 511 + 512
-
+
MA 08.02 - Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis
11:05 - 11:10 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA 07 - ALK, ROS and HER2
- Type: Mini Oral
- Track: Advanced NSCLC
- Presentations: 16
- Moderators:Robert C. Doebele
- Coordinates: 10/17/2017, 15:45 - 17:30, Room 316
-
+
MA 07.04 - Clinical Impact of Crizotinib on Brain Metastases in Patients with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer
16:00 - 16:05 | Author(s): L. Shen
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.01 - Advanced NSCLC
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 97
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.01-026 - Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Martin Schuler
- Abstract
Loading... -
+
P3.01-043 - Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung
09:30 - 09:30 | Author(s): Glenwood Goss
- Abstract
Loading... -
+
P3.01-052 - The Prevalence and Genotype Distribution of Dual in Cis EGFR Mutations in Chinese Advanced Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Presenter: Min Li
- Abstract
Loading... -
+
P3.01-070 - A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
09:30 - 09:30 | Presenter: Shun Lu
- Abstract
Loading... -
+
P3.01-075 - Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Vera Hirsh
- Abstract
Loading...
-
+
P3.02 - Biology/Pathology
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 106
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.02-014a - Diagnostic Value of FR+-CTCs Detected by LT-PCR for Lung Cancer in SPN and Tumor Invasiveness in Adenocarcinoma (T≪3cm)
09:30 - 09:30 | Presenter: Qianjun Zhou
- Abstract
Loading...
-
+
P3.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 15
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.04-005 - PD-L1 and Other Immuno-Markers Influenced by Osimertinib Treatment in Advanced Non-Small Cell Lung Cancer Patients (ATHENE Study)
09:30 - 09:30 | Author(s): Yongfeng Yu
- Abstract
Loading...
